New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women’s Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.